SCHEMBL5204699

SCHEMBL5204699

CCOC(=O)c1nc(CC)c(C)cc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.52
MAPK1 P28482 2/20 0.52
KMT2A Q03164 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
CYP1A2 P05177 2/20 0.44
ALDH1A1 P00352 3/20 0.42
GLP1R P43220 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
ADORA3 P0DMS8 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
CYP3A4 P08684 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TARBP2 Q15633 1/20 0.41
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13406205 0.76 KDM4E (0.50) KDM4EMAPK1KMT2AL3MBTL1CYP1A2
SCHEMBL1304956 0.75 HTT (0.47) KMT2ACYP1A2ALDH1A1TARBP2MAPT
SCHEMBL9869495 0.74 CA12 (0.42) KDM4EMAPK1KMT2AL3MBTL1ALDH1A1
SCHEMBL2409453 0.73 KDM4E (0.66) KDM4EMAPK1KMT2AL3MBTL1CYP1A2
SCHEMBL20657515 0.73 KDM4E (0.48) KDM4EMAPK1KMT2AL3MBTL1CYP1A2
SCHEMBL18560495 0.73 KDM4E (0.47) KDM4EMAPK1KMT2AL3MBTL1CYP1A2
SCHEMBL7361832 0.72 SMN1; SMN2 (0.50) KDM4EMAPK1KMT2ACYP1A2ALDH1A1
SCHEMBL6366583 0.72 KDM4E (0.55) KDM4EMAPK1KMT2AL3MBTL1ALDH1A1
SCHEMBL6644254 0.72 KDM4E (0.53) KDM4EMAPK1KMT2AL3MBTL1CYP1A2
SCHEMBL10003092 0.71 ALDH1A1 (0.42) KDM4EMAPK1CYP1A2ALDH1A1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1290448-B1 RARE EARTH METAL CRYPTATES SHOWING REDUCED FLUORESCENCE QUENCHING CIS BIO INT (FR) 2007-11-07 EP disclosed
US-7087384-B2 Rare earth metal cryptates which are not very sensitive to the fluorescence quenching CIS BIO INTERNATIONAL (FR) 2006-08-08 US disclosed
US-20040092726-A1 Novel rare earth metal cryptates which are not very sensitive to the fluorescence quenching CIS BIO INTERNATIONAL (FR) 2004-05-13 US disclosed
EP-1290448-A2 RARE EARTH METAL CRYPTATES SHOWING REDUCED FLUORESCENCE QUENCHING CIS BIO INTERNATIONAL (FR) 2003-03-12 EP disclosed
WO-2001096877-A2 RARE EARTH METAL CRYPTATES SHOWING REDUCED FLUORESCENCE QUENCHING CIS BIO INTERNATIONAL (FR) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092726-A1 Novel rare earth metal cryptates which are not very sensitive to the fluorescence quenching SQOR, MCU, NDUFS4 KDM4E 3781/4885MAPK1 4004/4885KMT2A 4400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.